- Benign Prostatic Hyperplasia
- Hormone Therapy
- Genomic Testing
- Next-Generation Imaging
- UTUC
- OAB and Incontinence
- Genitourinary Cancers
- Kidney Cancer
- Men's Health
- Pediatrics
- Female Urology
- Sexual Dysfunction
- Kidney Stones
- Urologic Surgery
- Bladder Cancer
- Benign Conditions
- Prostate Cancer
Study backs efficacy of podcasts for educating patients on genetic testing for prostate cancer
“It seems like podcasts really are a good way for people to learn about even a complex topic like this,” says Stacy Loeb, MD, MSc.
In this video, Stacy Loeb, MD, MSc, and Veda Giri, MD, discuss the findings of the paper, “Usefulness of podcasts to provide public education on prostate cancer genetics,” which was published in Prostate Cancer and Prostatic Diseases (https://rdcu.be/c3UEl).New episodes of the podcast discussed in the study will drop on Tuesdays (https://open.spotify.com/show/4FYxW2zUgJmW8wkVbiOXBb?si=dca177dda31443f6).
Giri is division chief of Clinical Cancer Genetics for Yale Cancer Center and Smilow Cancer and assistant director of Clinical Cancer Genetics for Yale Cancer Center, New Haven, Connecticut. Loeb is a professor in the departments of urology and population health at the NYU Grossman School of Medicine, New York City, New York.
Transcript:
Loeb: We wanted to make sure that this podcast series was really valuable, and there actually really haven't been a lot of scientific studies testing the utility of podcasts as an educational tool. It seems self-evident that something like this would be educational, but you don't really know. So we did a prospective study with participants from across the US. One group was patients with a history of prostate cancer. The other group was men and women with no specific cancer history. In both groups, we had them listen to the podcasts. They gave very high ratings in terms of usefulness, and they were able to correctly answer genetic questions after listening. So it seems like podcasts really are a good way for people to learn about even a complex topic like this.
Giri: Yes, and we're hopeful that that kind of data, when you actually study it, supports the potential for expanding on utilization of podcasts for dissemination of information about genetic testing for prostate cancer, for hereditary cancer testing, potentially even across different languages so that we really can start to bring this across populations. I think our data support that, and so we're very excited about that.
This transcript was edited for clarity.
Cell-cycle risk score is predictive of ADT benefit in prostate cancer
May 17th 2024"Prolaris precisely describes the difference in metastasis outcomes for men receiving monotherapy (RT) vs multimodal therapy (RT+ADT), and further tells me precisely what the risk of death is for a man on surveillance," says Jonathan D. Tward, MD, PhD.
